Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

183.64B

Market cap183.64B

Price-Earnings ratio

-55.75

Price-Earnings ratio-55.75

Dividend yield

2.16%

Dividend yield2.16%

Average volume

5.34M

Average volume5.34M

High today

$149.60

High today$149.60

Low today

$146.50

Low today$146.50

Open price

$148.00

Open price$148.00

Volume

5.26M

Volume5.26M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$108.46

52 Week low$108.46

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $147.25. The company's market cap stands at 183.64B, with a P/E ratio of -55.75 and a dividend yield of 2.16%.

As of 2026-08-26, Gilead Sciences(GILD) stock has fluctuated between $146.50 and $149.60. The current price stands at $147.25, placing the stock +0.5% above today's low and -1.6% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 5.26M, against a daily average of 5.34M.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

GILD News

Nasdaq 12h

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

Key Points Gilead reported big losses last quarter, but this could pave the way for its diversification into oncology. In the meantime, investors remain focus...

MarketWatch 1d

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

...

Nasdaq 3d

Gilead: European Commission Approves Trodelvy Plus Keytruda In PD-L1-positive Metastatic TNBC

(RTTNews) - Gilead Sciences (GILD) announced the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treat...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

20%

Sell

3.3%

More GILD News

TipRanks 3d

Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination

Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of...

Simply Wall St 5d

Can Gilead Sciences Justify Its Valuation On The Nucleai Oncology AI Deal?

Nucleai’s new collaboration with Gilead Sciences (GILD) centers on AI driven analysis of tissue samples to support antibody drug conjugate programs across sever...

Simply Wall St 6d

Gilead Stock Still Looks Below Fair Value As Court Backs HIV Import Block

Gilead Sciences stock has delivered very strong long term returns over the past five years, yet current valuation checks and market multiples still point to the...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.